Close Menu

NEW YORK (GenomeWeb) – 23andMe said today that it has received FDA clearance for a genetic health risk report for a syndrome associated with a higher risk of developing hereditary colorectal cancer.

The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MUTYH-associated polyposis (MAP), which confers a high risk for developing large numbers of pre-cancerous polyps, in turn increasing the risk for the development of CRC.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.